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Abstract
Neuroendocrine neoplasms (NENs) show wide spectrum of clinical course — from benign biological potential to recurrences 
and rapidly progressive disease. Somatostatin analogs that bind to somatostatin receptor are part of the therapy; detection 
and evaluation of activation of somatostatin receptor subtypes are part of the process of new therapy induction. When using 
RT-PCR method and immunohistochemistry, it is possible to detect more than two SSTR subtypes in majority or all neuroendo-
crine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site 
of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% 
(G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indi-
cate significant differences in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type.
Further research on SSTRs expression in NEN could serve as base to development and improvement of somatostatin analogs’ 
pharmacotherapy in patients with unsatisfactory course.
KEY words: somatostatin, somatostatin receptor, SSTR, neuroendocrine neoplasm, NEN, expression
Nucl Med Rev 2016; 19, 2: 111–117
Introduction
Somatostatin analogs take a role in pharmacotherapy from the 
early 1980s [1]. Somatostatin binds to all somatostatin receptor 
subtypes (SSTR 1–5), in contrast to octreotide (first synthesized 
somatostatin analog) and lanreotide, which bind only with a high af-
finity to SSTR 2 and SSTR 5 [2, 3]. Expression of somatostatin recep-
tors by endocrine tumors is essential for the use of the somatostatin 
analogs in pharmacotherapy. In 1973, somatostatin was isolated 
from sheep hypothalami in the search for the hormone responsible 
for stimulating the release of GH from the anterior pituitary [4]. 
Many physiological functions in the GI tract (e.g. motility, gastric 
acid production, pancreatic enzyme secretion, bile secretion) are 
inhibited by somatostatin. It also acts as a secretory pan-inhibitor, 
by suppressing secretion from the anterior pituitary gland (e.g. GH, 
prolactin, TRH, ACTH) [5–7], gastrointestinal tract (e.g. cholecys-
tokinin, gastrin, secretin, vasoactive intestinal peptide), endocrine 
pancreas (e.g. glucagon, insulin, and pancreatic polypeptide) [8], 
thyroid (e.g. triiodothyronine, thyroxin, and calcitonin), kidney and 
adrenals (e.g. renin aldosterone system) [9]. Control of the cell pro-
liferation in normal tissues and tumors was as well recorded [10–13].
Two biologically active forms of somatostatin: somatostatin-14 
and somatostatin-28 act through high affinity G protein-coupled 
membrane receptors. Proteolytic processing of larger precursor 
molecules (prepro-somatostatin and pro-somatostatin) forms the 
somatostatin [14, 15]. Five somatostatin receptor (SSTR) subtype 
genes have been cloned and described — SSTR 1, SSTR 2, SSTR 3, 
SSTR 4 and SSTR 5 [16]. The genes which encode the five SSTR 
subtypes are localized on different chromosomes [17]. Alternative 
splicing can generate two forms of the SSTR2 receptor (SSTR 2A 
and SSTR 2B) [18, 19]. 
Somatostatin influence on cells has a wide spectrum, through 
binding to its SSTR subtype(s), and activation of the second 
messenger system. These systems include (1) inhibition of ade-
nylate cyclase activity and (2) activity of calcium channels, as well 
as (3) stimulation of phosphotyrosine phosphatase or (4) MAPK 
(mitogen-activated protein) kinase activity [17, 20, 21]. The inhibi-
tory effects of somatostatin on adenylate cyclase activity and on 
the influx of calcium are linked to inhibition of secretion processes. 
Activation of SSTR 1, 2, 4 and 5 promotes cell cycle arrest (via 
modulation of MAPK pathway) [22, 23]. Interestingly, SSTR 2 and 
SSTR 3 trigger apoptosis (accompanied by p53 and Bax protein 
activation) [24–26].
A high density of SSTRs are expressed in tumors, arising from 
tissues which are target for the somatostatin [27–31].
Many tumors express the SSTR: e.g. pituitary adenomas, pan-
creatic endocrine tumors, carcinoids, paragangliomas, pheochro-
mocytomas, small cell lung cancers, medullary thyroid carcinomas, 
breast cancers and malignant lymphomas [28, 32]. 
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Multiple SSTR subtypes are coexpressed by the majority of the 
SSTR-positive tumors and essential variation in their expression 
between the different tumor types and among tumors of the same 
type were described [33–36].
SSTR 2 predominance is generally found in more than 80% 
of the endocrine pancreatic and endocrine GI tract tumors [29, 
31, 37–39].
Different methods have been used for identification SSTR 
subtypes expression in tissue samples. The most relevant are: the 
specific mRNA of SSTR detection (e.g. in situ hybridization, RNase 
protection assays and RT-PCR), using radiolabeled somatostatin 
analogs and immunohistochemistry. IHC based on SSTR-specific 
antibodies seems to be widely available and cost effective method 
which identifies SSTR subtypes — it is worthy to mention that many 
researchers noticed that this method needs the precise standardi-
zation [40–48].
Many articles bring information about SSTR expression using 
the nuclear medicine methods — for this knowledge we send the 
reader to the references [49–54].
Pituitary adenoma
Pituitary adenomas (PA) in the majority have a benign biological 
potential. These tumors are classified based on the hormones that 
are produced by the neoplastic cells (GH, prolactin, adrenocorti-
cotropin, thyrotropin, follitropin, or luteinizing hormone) — some 
of them can secrete two hormones (GH and prolactin as the most 
common combination), and rarely, pituitary adenomas are pluri-
hormonal. Clinically non-functioning adenomas (CNFA) lack the 
typical hypersecretion of the functional pituitary adenomas and do 
not produce clinical symptoms of hormone excess.
Recent data based on mRNA and immunohistochemistry 
analysis showed that in (GH) adenomas SSTR 2, SSTR 5, SSTR 
3 and SSTR 1 transcripts were expressed in descending level 
order. Macroprolactinomas revealed significant amount of SSTR 1 
transcripts. Corticotroph adenomas showed expression of SSTR 2 
and SSTR 1 transcripts, but levels of SSTR 5 transcripts were very 
low. Patients with CNFA dominantly expressed SSTR 3 and SSTR 
2mRNA [55], other data demonstrate expression of SSTR 1-5 by all 
CNFA, but with very low/or missing levels of SSTR 4 and 5 [56–58]. 
High relative expression (ratio to b-glucuronidase mRNA > 1) of 
SSTR 1 was found in 7.5 %, SSTR 2 in 7 %, SSTR 3 in 4 % and SSTR 
5 in 0.5 % of tumors. Among histological adenoma types in null cell 
adenomas high levels of SSTR 1 and SSTR 2 were observed, ac-
companied with low levels of SSTR 3. In gonadotrophs adenomas, 
expression of SSTR 3, SSTR 2 and SSTR 1 in descending order 
was demonstrated. Silent ACTH adenomas showed expression of 
SSTR 2, SSTR 1, SSTR 5 and low level of SSTR 3 [56]. In recent 
years, scientist investigate coexpression of the SSTRs and other 
receptors in many neuroendocrine neoplasms (e.g. dopamine 2) 
[55, 56].
Gastro-intestinal tract and Pancreas
Neuroendocrine neoplasms (NEN) in the digestive system 
and pancreas are divided into neuroendocrine tumors (NET; low to 
intermediate grade, G1 and G2 respectively) and neuroendocrine 
carcinomas (NEC; poorly differentiated — high grade, G3). Among 
NECs, large cell NEC and small cell NEC can be recognized. Mixed 
adenoneuroendocrine carcinomas (MANEC) are neoplasms with 
both high grade neuroendocrine and adenocarcinoma features. 
Classification criteria of NENs are common to all GI and pan-
creatic neuroendocrine neoplasms. NENs can be functional or 
non-functional [59].
Grossly NETs have tendency to be small, circumscribed, and 
in GI tract they can be covered by a flattened mucosa [60] or have 
the gross appearance of gastric polyps [61]. Microscopically, the 
predominant pattern of growth may be microglandular, trabecular 
or insular. The nuclei are regular and normochromatic, mitoses are 
scanty, necrosis is usually absent, and vascularization is florid. 
Focal mucin positivity may be present. Immunohistochemically, 
GI NENs are positive for neuron-specific enolase, chromogranin, 
synaptophysin, and keratin. NECs may form a large, sometimes fun-
gating mass deeply infiltrating the GI wall and often metastatic 
to lymph nodes and liver. They are composed of large, poorly 
formed trabeculae, nests or sheets of anaplastic round, polyhedral 
to spindle cells, small to fairly large in size, and immunoreactive 
for general neuroendocrine markers including chromogranin A, 
synaptophysin, neural cell adhesion molecule (NCAM1/CD56) or 
neuron-specific enolase [59].
Immunohistochemistry revealed that SSTR 1, SSTR 2A, 3 and 5 
are expressed in gastrinomas, insulinomas and carcinoid tumors. 
Immunostaining of the specific antibodies is non-homogenous and 
shows differences between SSTR subtypes and between commer-
cial antibodies. Generally immunoreactivity for SSTR 2 is localized 
in the plasma membrane in contrast to SSTR 1, 3 and 5 which stain 
mainly the cytoplasm.
SSTR 1 was expressed in 30% of gastrinomas, 31% of insu-
linomas ad 37% of NETs. SSTR 2a showed expression in 100% of 
gastrinomas, 58% of insulinomas and 86% of NETs. Immunostaining 
for SSTR 3 was observed in 79% of gastrinomas, 78% of insulino-
mas and 71% of NETs. SSTR 5 immunoreactivity was detected in 
of 76% gastrinomas, 78% of insulinomas and 83% of NETs [62]. 
Other researchers also indicate SSTR 2 as the commonest SSTR 
expressed, which is accompanied by co-expression of SSTR 3 and 
5 in 32% and 24% of cases, respectively [63].
From the viewpoint of tumor localization: 85.5% of pancreatic, 
100% of gastric, 70% of intestinal, 85.7% of appendiceal and 100% 
of rectal NENs show SSTR 2. SSTR 5 expression in present in: 
61.9% of pancreatic, 37.5% of gastric, 70% of intestinal, 71.5% of 
appendiceal and 66.6% of rectal NENs. According to the tumor 
grade, SSTR 2 is expressed in 91% of grade1, 82.8% of grade 2 
and 100% of grade 3 GI NENs. SSTR 5 show expression in 81.8%, 
60% and 0% of grade 1, 2 and 3, respectively [64].
Lung
The pulmonary neuroendocrine tumors include typical carcinoid 
(TC), atypical carcinoid (AC), small cell carcinoma (SCLC) and 
large cell neuroendocrine carcinoma (LCNEC). These tumors are 
characterized by similar microscopic appearance, like other neu-
roendocrine tumors in the body — they have organoid nesting, 
palisading and trabecular pattern with mitotic activity and presence 
of necrosis as the distinguishing features (TC: < 2 mitoses per 
2 mm2 and no evidence of necrosis. AC: 2–10 mitoses per 2 mm2 
and/or focal necrosis).
113www.nmr.viamedica.pl
Jerzy Hankus, Romana Tomaszewska, Neuroendocrine neoplasms and somatostatin receptor subtypes expression
Review
LCNEC is differentiated from SCLC by larger cell size, abun-
dant cytoplasm and prominent nucleoli. Mitotic activity is high 
(10–11 mitoses/10 hpf). Prominent nuclear molding and deposition 
of hematoxylin-stained material (DNA) in blood vessel walls are 
characteristic for SCLC. These tumors are positive for chromogra-
nin, synaptophysin and NCAM (CD56), about 50% of LCNECs also 
express TTF-1.
TC and AC occur in significantly younger patients than SCLC 
and LCNEC. They present as firm and well-demarcated tumors, 
with predilection to bronchi (frequently endobronchial growth). TC 
is evenly distributed in the lung parenchyma, while AC arises more 
commonly in small peripheral bronchi. Clinical symptoms are re-
lated to bronchial obstruction (cough and hemoptysis as the most 
common), Cushing’s syndrome and carcinoid syndrome are rare.
SCLC has tendency to occur in central location with locoregio-
nal spread, commonly accompanied by paraneoplastic syndromes. 
On macroscopy it presents as a white-tan, soft and friable mass with 
extensive necrosis and frequent nodal involvement.
LCNEC occurs preferentially as peripheral mass, but may 
also involve subsegmental or large bronchi. It spreads on visceral 
pleura and chest wall. Typically LCNECs do not produce clinical 
symptoms of hormone excess [65–70].
Typical carcinoids (TC) show immunoexpression of SSTR 1, 2A, 
2B, 3, 4, and 5 in 79%, 96%, 66%, 49%, 5%, and 0%, respectively. 
Atypical carcinoids (AC) expression of SSTR 1, 2A, 2B, 3, 4, and 5 
was observed in 77%, 77%, 77%, 33%, 0% and 0%, respectively. 
In Large cell NECs (LCNEC), immunoexpression of SSTR 1, 2A, 
2B, 3, 4, and 5 was observed in 60%, 60%, 30%, 40%, 0%, and 
15% of cases, respectively. Small-cell carcinomas (SCLC) show 
immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 in 27%, 69%, 
24%, 15%, 0%, and 0% of cases, respectively.
Tsuta et al. demonstrated that SSTR 1, 2A, 2B, 3 and 4 have 
a tendency toward decreased expression in well to poorly differ-
entiated NECs [71].
Other study of TC and AC [58] also indicates SSTR 2A as a most 
frequently expressed (72% of cases), followed by SSTR 1 (63%), 
SSTR 5 (40%) and SSTR 3 (20%), whereas researchers did not 
record SSTR 4 expression. 
83% of TCs and ACs are positive for at least one SSTR subtype, 
these which are negative for SSTR 2A, show expression of another 
SSTR in nearly half cases (48%) — among them 35% are positive 
for SSTR 1, 11% for SSTR 3 and 11% for SSTR 5.
There is no difference in distribution of SSTR 1–5 compared 
with TNM parameters [72].
Paraganglioma/pheochromocytoma
Pheochromocytoma (PCC) and paraganglioma (PGL) are 
neuroendocrine tumors derived from adrenal chromaffin cells and 
extra-adrenal paraganglia, respectively. Hereditary tumors are 
frequently diagnosed before 40 years of age, while sporadic tu-
mors are usually discovered in patients aged 40 to 50 years. Clini-
cal presentation results from effects of secreted catecholamines, 
including: hypertension, tachycardia, pallor, headache, and anxiety; 
but up to 25% of pheochromocytomas are asymptomatic. Macro-
scopically tumors are variable in size and weight (up to > 2000 g), 
with round to oval and sharply circumscribed presentation. Cut 
surface shows a dusky red-brown mass with possible marked 
hemorrhage and necrosis. Tumor cells vary in size and shape and 
show round nuclei, prominent nucleoli and granular amphiphilic to 
basophilic cytoplasm. They are arranged in well-defined nests (Zell-
ballen), surrounded by the sustentacular cells. Cell nests can be 
separated by thin strands of fibrovascular stroma.
Patients with MEN II syndrome may demonstrate tumors ac-
companied by adrenal medullary hyperplasia, occasionally multiple 
or bilateral [73–76].
Among SSTRs, type 2 and 1 are the most commonly expressed 
subtypes in PCCs and PGLs. Expression of SSTR 3 and SSTR 5 
is more frequent in PCCs than PGLs. More precise data show SSTR 
expression level in PCCs: 95%, 100%, 56% and 54% for SSTR 
1, 2, 3 and 5, respectively. SSTR 1, 2, 3 and 5 are expressed in 
PGLs in: 92%, 100%, 31% and 31%, respectively. Researchers did 
Figure 1. Medullary thyroid carcinoma — SSTR 1. Medullary thyroid 
carcinoma (upper left) show weak SSTR 1 expression
Figure 2. Medullary thyroid carcinoma — SSTR 2a. Medullary thyroid 
carcinoma (upper left) show SSTR 2a expression
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not indicate significant differences in SSTRs expression between 
sporadic and hereditary tumor types [77].
Merkel cell carcinoma
Merkel cell carcinoma is an uncommon neoplasm of the skin with 
neuroendocrine differentiation, which involves commonly head and 
extremities. It is usually small (from 0.8 cm to 4 cm), pink, solitary no-
dule, rarely with multiple nodules presentation. Tumor is composed of 
small, round, blue cells with scant cytoplasm and irregular nuclei with 
uniformly distributed chromatin. Nucleoli are inconspicuous, frequent 
mitotic figures and individually necrotic tumor cells are commonly 
visible. Tumor cells are positive for chromogranin, synaptophysin, 
neuron-specific enolase and cytokeratin 20 [78–83].
Overall, 76.5% of Merkel cell carcinomas express at least one of 
SSTRs. SSTR 2A and SSTR 5 are expressed in 59.2% and in 44.9% 
of tumors, respectively. Expression of SSTRs is not associated with 
clinical characteristics, Ki67 proliferative index and survival [84].
Neuroblastoma
Neuroblastoma is the most common solid tumor of young chil-
dren (90% occur < 5 years); it shows minimal to none maturation 
and is composed of small round blue cells arranged in nodular 
aggregates separated by fibrovascular septa. Homer-Wright 
pseudorosettes can be visible. Macroscopically tumor forms large 
mass with a gray cut surface, often accompanied by hemorrhage 
and necrosis. Neuroblastoma cells are positive for neurofilament, 
synaptophysin, chromogranin and neuron-specific enolase [85–90].
Neuroblastomas show expression in 66.7%, 81.5%, 9.3%, 37% 
and 0% for SSTR 1, 2, 3, 4 and 5 respectively. The favorable histo-
logy group of NBs are characterized by higher SSTRs expression 
than the unfavorable histology group — the researchers indicate 
significant differences in SSTR 1, 2 and 4 expression. SSTR sub-
types expression in normal tissues from the adrenal medulla and 
sympathetic ganglia are similar to those of ganglioneuromas and 
ganglioneuroblastomas, with rates being 100% for SSTR 1, ap-
proximately 90% for SSTR 2, approximately 40% for SSTR 3, 100% 
for SSTR 4 and 0% for SSTR 5 [91].
Medullary thyroid carcinoma
Medullary thyroid carcinoma is a malignant entity derived from C 
cells and accounts for up to 5% of thyroid malignancies. Tumor can 
be sporadic (80%) or hereditary (20%, related to familial medullary 
thyroid carcinoma, MEN IIA and MEN IIB). Elevated level of calci-
tonin in serum is a useful parameter to monitor residua, recurrent 
or metastatic disease. Macroscopically tumor occurs often as cir-
cumscribed, tan-yellow mass with firm consistency. Most common 
localization is upper and middle third of lobe (which corresponds to 
predominant C cells localization); in hereditary types multifocal 
nodules may occur. Medullary thyroid carcinoma presents variety 
of histologic patterns: solid, sheet-like, lobular, trabecular and 
insular. Tumor cells are round, polygonal, fusiform and commonly 
mixed cell types are visible, with salt-pepper chromatin pattern 
appearance. Stromal deposition of amyloid occurs in about 80% 
of cases. Immunohistochemistry reveals positive reaction to calci-
tonin, chromogranin, synaptophysin, carcinoembryonic antigen and 
TTF 1. Congo red stains amyloid material and shows birefringence 
in polarized light [92–95].
Researchers demonstrated SSTRs by IHC in medullary thyroid 
carcinoma in 1970s and 1980s, later works showed that 85% of 
tumors express at least one SSTR; 49%, 43%, 47%, 4% and 57% 
tumors are positive for SSTR 1, 2, 3, 4 and 5, respectively. There 
is no correlation between SSTR expression and clinical data, TNM 
and histological type [96].
Others studies analyzed SSTR expression in other thyroid malig-
nancies — they also showed that SSTR 5 is commonly expressed in 
thyroid neoplastic and non-neoplastic entities (86.2–100%) [97–98].
Summary
Using RT-PCR method and immunohistochemistry it is pos-
sible to detect more than two SSTR subtypes in majority or all 
neuroendocrine neoplasms regardless tumor origin. Generally with 
some exceptions, from the viewpoint of tumor grade — apart the 
site of origin, there is a tendency to decrease the percentage of 
SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% 
(G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 
3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indicate 
significant difference in the expression of SSTR 1 and 2A and 2B 
between NEC G3 small cell type and non-small cell type [71, 99].
Further research on SSTRs expression in NEN could serve 
as a base for development and improvement of somatostatin 
analogs’ pharmacotherapy in patients with unsatisfactory course.
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